Perrigo Company asserted that it sought tentative approval from the U.S Food and Drug Administration for the generic version of Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). Onexton Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Branded market sales for the last 12 months were pegged at $115 million.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated claimed “This tentative approval is another example of making long-term investments in our extended topicals strategy. The Rx team continues to invest in bringing important products to market that provide savings to patients and healthcare systems.”